Literature DB >> 16555127

Effect of vinca alkaloids on ERalpha levels and estradiol-induced responses in MCF-7 cells.

Carlos Martínez-Campa1, Pedro Casado, René Rodríguez, Pedro Zuazua, Juana M García-Pedrero, Pedro S Lazo, Sofía Ramos.   

Abstract

Vinca alkaloids (VAs) such as Vincristine, Vinblastine and Vinorelbine are antineoplastic drugs that inhibit tubulin polymerisation into microtubules, induce mitotic G2/M arrest, activate c-Jun N-terminal kinase (JNK) and induce apoptosis. Although there are many studies evaluating the effect of VAs on breast cancer patients, until now little was known about how these compounds and estradiol signaling pathways might interfere. In this report, we show for the first time that VAs decreased ERalpha protein levels in the human breast cancer cell line MCF-7; VAs induced a parallel decrease in estrogen receptor mRNA. All the VAs tested inhibited estradiol (E2) mediated transactivation at ERE-driven promoters. E2 inhibited VAs-induced AP1 stimulation in MCF-7, but this inhibition was not observed when E2 is added 24 h in advance of VAs treatment. In contrast to the reported preventing effect over taxol-mediated apoptosis, E2 did not prevent VAs-induced cell death and interestingly, addition of E2 24 hours in advance of VAs treatment resulted in an increase of the number of cells undergoing apoptosis. Similar results were observed when E2 is replaced by other proliferation signals such as EGF. These results demonstrate that in the breast cancer cell-line MCF-7, E2-induced proliferation before VAs treatment enhances the apoptotical response to VAs which might have important implications in clinica.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555127     DOI: 10.1007/s10549-005-9134-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  Towards novel anti-tumor strategies for hepatic cancer: ɛ-viniferin in combination with vincristine displays pharmacodynamic synergy at lower doses in HepG2 cells.

Authors:  Filiz Özdemir; Gülşen Akalın; Mesut Şen; Nur Ipek Önder; Arzu Işcan; H Mehtap Kutlu; Zerrin Incesu
Journal:  OMICS       Date:  2013-12-17

Review 2.  Molecular insight into the therapeutic potential of phytoconstituents targeting protein conformation and their expression.

Authors:  Vishvanath Tiwari
Journal:  Phytomedicine       Date:  2018-09-26       Impact factor: 5.340

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.